Rapid Diagnostic Test for Malaria detection in Saliva samples

BNITM, with support from the RIGHT Foundation, is developing a novel, non-blood-based malaria diagnostic test to overcome limitations associated with blood sampling. The prototype Lateral Flow (LF) test will use Plasmodium Topoisomerase 1 (pTOP1) as a biomarker, offering improved sensitivity over existing rapid tests while maintaining simplicity for home and field use. Clinical validation will take place primarily in Gabon, Benin, and South Korea, with potential expansion to Ghana, Kenya, and Mozambique. Malaria remains a major global burden, with 247 million cases and 619,000 deaths in 2021, disproportionately affecting Africa. BNITM’s innovative approach will provide a reliable, accessible alternative to traditional microscopy, reducing diagnostic barriers in high-risk regions. This rapid test will enhance early detection, support malaria elimination efforts, and improve healthcare access in endemic areas.